drug · antibody drug conjugate

ZYNLONTA

updated 3mo ago

/ LON-kas-TUK-si-mab /

by $ADCT ADC Therapeutics SA🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 5 investigational indications.

targets

B-lymphocyte antigen CD19

all catalysts(0)

nothing on the calendar yet

News(5)

Aura, Schrödinger trim workforces
Follow along as BioSpace tracks job cuts and restructuring initiatives.
biospace · 7h ago
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…
biospace · 8d ago
An ADC specialist sinks on safety concerns for blood cancer drug
Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
biopharma_dive · 2mo ago
ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...
endpoints · 2mo ago
Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
fiercebiotech · 7mo ago

brand

ZYNLONTA

trade names

Zynlonta

generic

LONCASTUXIMAB TESIRINE-LPYL

MOA

12.1 Mechanism of Action Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine-lpyl is internalized followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had anticancer activity in animal models of lymphoma.

indication

1 INDICATIONS AND USAGE ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. ( 1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 17m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(5)

Aura, Schrödinger trim workforces

Follow along as BioSpace tracks job cuts and restructuring initiatives.

biospace · 7h ago

BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech

BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…

biospace · 8d ago

An ADC specialist sinks on safety concerns for blood cancer drug

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”

biopharma_dive · 2mo ago

ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates

ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...

endpoints · 2mo ago

Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

fiercebiotech · 7mo ago

ZYNLONTA

🐶 often sniffed alongside

targets

all catalysts(0)

News(5)

Report a data issue

comments(0)

ZYNLONTA

🐶 often sniffed alongside

targets

all catalysts(0)

News(5)

Report a data issue

comments(0)